Meet the La Jolla researcher who helped discover new muscular dystrophy drug
Having found that in biomedical research, the Bird Rock resident and scientist at La Jolla’s Sanford Burnham Prebys has ...
The American Journal of Managed Care1d
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature ...
Researchers identify link to kidney in myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1), a genetic disorder, shares overlapping features with chronic kidney disease, including ...
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and ...
Science Daily7d
Scientists unlock clues to new treatments for muscular dystrophy
Researchers combined advanced imaging techniques and theoretical physics to observe and explain how nanoclusters of the protein emerin form inside living cells. The study uncovers the molecular 'rules ...
How you can help a 10-year-old Kingman boy with muscular dystrophy gain more freedom
Dominic Olsen is a bright and determined 10-year-old boy living with Duchenne Muscular Dystrophy, a rare disease that has ...
Shamrocks MDA, supporting those with muscular dystrophy: Live on GMI
Roland Beres sits down with April Gannon of the Muscular Dystrophy Association to discuss the importance of raising money and ...
AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Dosing of First Participant in Second Cohort
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced the advancement of the Phase 1/Phase 2 LION-CS101 clinical trial of ...
Morningstar2d
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
will present topline del-zota data from Avidity's Phase 1/2 EXPLORE44 trial for people living with Duchenne Muscular Dystrophy amenable to exon 44 skipping (DMD44). March 16-18, 2025: 6:00 p.m ...